Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2018

Balance Sheet Components

Schedule of cash equivalents and available-for-sale securities

Cash equivalents and available-for-sale securities consisted of the following (in thousands):

	March 31, 2018
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Money market funds	$	68,088	$	—	$	—	$	68,088
Corporate bonds		6,792		—		(27)		6,765
Commercial paper		2,892		—		—		2,892
Government bonds		61,436		—		(153)		61,283
Total cash equivalents and available-for-sale securities	$	139,208	$	—	$	(180)	$	139,028
Classified as:
Cash equivalents							$	68,088
Available-for-sale securities - current								65,383
Available-for-sale securities - noncurrent								5,557
Total cash equivalents and available-for-sale securities							$	139,028

	December 31, 2017
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Money market funds	$	48,704	$	—	$	—	$	48,704
Corporate bonds		6,254		—		(7)		6,247
Commercial paper		58,524		—		—		58,524
Government bonds		40,428		—		(125)		40,303
Total cash equivalents and available-for-sale securities	$	153,910	$	—	$	(132)	$	153,778
Classified as:
Cash equivalents							$	104,348
Available-for-sale securities - current								37,972
Available-for-sale securities - noncurrent								11,458
Total cash equivalents and available-for-sale securities							$	153,778

Summary of Accrued Expenses and Other Payables

Accrued expenses and other payables consisted of the following (in thousands):

	March 31,		December 31,
	2018		2017
Accrued clinical and research related expenses	$	8,277	$	6,437
Accrued employee related expenses		1,267		2,718
Accrued professional service fees		486		267
Other		328		124
Accrued expenses and other payables	$	10,358	$	9,546